3 results
The primary objective of this study is to evaluate the target engagement of AZD4831, MPO inhibitor by measuring MPO specific activity in plasma following ex vivo stimulation of fresh blood samples with zymosan, in patients with HFpEF. MPO is known…
This study aims to evaluate the effect of AZD4831 on functional improvement and reduction of symptoms in participants with heart failure with left ventricular ejection fraction > 40%. Additionally, the PK and overall safety profile of AZD4831…
Primary: To characterize safety and tolerability of TNO155 and identify a recommended dose and regimen for future studies in adult patients with advanced solid tumors. And a recommended dose of TNO155 in combination with nazartinib in patients with…